Novartis | NOVN - Kewajiban Lancar





Kewajiban Lancar Perubahan Tanggal
AbbVie USD 41.64B 458M 2026-06
Alcon AG USD 3B 45M 2026-03
Almirall EUR 323.65M 26.99M 2026-06
Amgen USD 25.5B 547M 2026-06
AstraZeneca USD 31.55B 1.02B 2026-06
Autolus Therapeutics Ltd USD 63.6M 9.84M 2026-03
Bayer EUR 33.46B 875M 2026-03
Biogen USD 3.92B 918.2M 2026-06
Bristol-Myers Squibb USD 18.66B 499M 2026-06
Eli Lilly USD 47.74B 11.11B 2026-06
Fresenius EUR 9.07B 468M 2026-06
Fresenius Medical Care EUR 6.73B 484.42M 2026-03
Genmab DKK 1.14B 38M 2026-06
Gilead Sciences USD 11.02B 1.54B 2026-06
GlaxoSmithKline GBP 21.53B 895M 2026-06
GRIFOLS EUR 2.24B 112M 2026-06
Hikma Pharmaceutical USD 1.45B 603M 2025-12
J&J USD 54.9B 2.82B 2026-06
Lakefront Biotherapeutics EUR 100.42M 52.44M 2026-03
Lonza CHF 3.57B 421M 2025-12
Merck EUR 9.35B 307M 2026-03
Merck USD 27.73B 786M 2026-06
Novartis USD 31.75B 374M 2026-06
Novartis USD 31.37B 4.1B 2026-03
Novo Nordisk DKK 239.08B 13.92B 2026-06
Orion EUR 454.5M 344.1M 2026-06
Pfizer USD 32.65B 1.7B 2026-06
Philips EUR 7.42B 8M 2026-06
Recordati EUR 1.4B 30.88M 2026-06
Regeneron Pharmaceuticals USD 5.53B 422.9M 2026-06
Roche Holding CHF 28.85B 846M 2026-06
Sanofi EUR 31.93B 1.92B 2026-06
UCB EUR 4.4B 470M 2025-12